The Gold Standard is a workplace- based program that focuses on lowering the risk of cancer.
The Life Sciences Consortium (LSC) brings together oncology companies to accelerate discovery and development of new therapies for all cancer patients. Visit Website
The CEO Roundtable on Cancer currently has two Task Forces: the CEO Cancer Gold Standard (“Gold Standard”) Task Force and the Life Sciences Consortium (LSC) Task Force. The CEO Cancer Gold Standard™ created by the Member CEOs in 2004, is a workplace wellness accreditation program designed to encourage healthy behaviors and improve health outcomes for employees by promoting prevention measures, encouraging early detection through cancer screenings, and ensuring access to quality care.
The LSC was formed in 2005 to bring together leading oncology pharmaceutical/biotechnology companies to build collaboration in cancer drug development. The goal of these collaborations is a transformation in research and development that will effectively deliver new agents to prevent and treat cancer and fulfill the promise of our emerging understanding of cancer biology. This collaboration focuses on exploring and solving issues common to all cancer companies engaged in drug discovery and development that cannot be solved by any company alone.